Understanding Haemonetics ( HAE ) Reliance on International Revenue
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results - Haemonetics ( NYSE:HAE )
Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday. The company posted quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 per share. The company reported quarterly sales of $321.394 million which beat the analyst consensus ...
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Crocs ( NASDAQ:CROX ) , Haemonetics ( NYSE:HAE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Haemonetics ( HAE ) Q1 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of +8.91% and +5.97%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics ( HAE ) Q1 Revenue Falls 4%
Haemonetics ( NYSE:HAE ) , a medical technology company specializing in blood and plasma collection and hospital technologies, reported its financial results for the first quarter of fiscal 2026 on August 7, 2025. The main headlines from the release included GAAP revenue of $321.4 million for Q1 ...
Peering Into Haemonetics's Recent Short Interest - Haemonetics ( NYSE:HAE )
Haemonetics's HAE short percent of float has fallen 4.44% since its last report. The company recently reported that it has 3.50 million shares sold short, which is 11.84% of all regular shares that are available for trading.
Unlocking Q1 Potential of Haemonetics ( HAE ) : Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Analysts Estimate Haemonetics ( HAE ) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific ( BSX ) Q2 Earnings and Revenues Surpass Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of +4.17% and +3.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Peering Into Haemonetics's Recent Short Interest - Haemonetics ( NYSE:HAE )
Haemonetics's HAE short percent of float has fallen 9.76% since its last report. The company recently reported that it has 3.66 million shares sold short, which is 12.39% of all regular shares that are available for trading.
Integer Appoints Michael Coyle to Board of Directors - Integer Holdings ( NYSE:ITGR )
~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~
Integer Appoints Michael Coyle to Board of Directors
~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ...
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
Haemonetics ( HAE ) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of 1.64% and 1%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho ( QDEL ) Q1 Earnings and Revenues Top Estimates
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 27.59% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Haemonetics ( HAE ) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Haemonetics ( HAE ) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
How Do Investors Really Feel About Haemonetics? - Haemonetics ( NYSE:HAE )
Haemonetics's HAE short percent of float has fallen 24.83% since its last report. The company recently reported that it has 4.53 million shares sold short, which is 14.26% of all regular shares that are available for trading.
Vascular Closure Device Market Size Projected to Grow to USD 3.03 Billion by 2030, Fuelled by Cardiovascular Disease Prevalence and Minimally Invasive Trends - The Insight Partners
US & Canada, April 03, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Apr, 01, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, "Vascular Closure Device Market Size and Forecast ( 2020-2030 ) , Global and Regional Share, Trend, and Growth Opportunity Analysis ...
Medtronic ( MDT ) Up 5.6% Since Last Earnings Report: Can It Continue?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
How Do Investors Really Feel About Haemonetics? - Haemonetics ( NYSE:HAE )
Haemonetics's HAE short percent of float has risen 30.22% since its last report. The company recently reported that it has 6.83 million shares sold short, which is 21.5% of all regular shares that are available for trading.
Sotera Health ( SHC ) Q4 2024 Earnings Call Transcript
SHC earnings call for the period ending December 31, 2024.
Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook
CLEVELAND, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Sotera Health Company ( "Sotera Health" or the "Company" ) ( Nasdaq: SHC ) , a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial ...
( HAE ) - Analyzing Haemonetics's Short Interest - Haemonetics ( NYSE:HAE )
Haemonetics's HAE short percent of float has risen 5.7% since its last report. The company recently reported that it has 5.24 million shares sold short, which is 16.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.94 days to cover ...
HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.
Haemonetics ( HAE ) Q3 Earnings Meet Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of 0% and 1.30%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
How Is The Market Feeling About Haemonetics? - Haemonetics ( NYSE:HAE )
Haemonetics's HAE short percent of float has fallen 5.16% since its last report. The company recently reported that it has 4.96 million shares sold short, which is 15.62% of all regular shares that are available for trading.
Is Omnicell Stock a Solid Pick for Your Portfolio Right Now?
OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.
ResMed Q2 Earnings and Revenues Beat, Stock Up in Pre-Market
RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up
In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise
Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties.
CALID Arm Growth to Support Bruker Shares Amid Macro Issues
BRKR's NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?
TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch
IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.
Strategic Acquisitions to Support STERIS Stock Amid Macro Issues
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
ABT delivers a strong underlying base business performance for the fourth quarter of 2024.
Prestige Consumer Stock Up 29.9% in a Year: What's Behind the Surge?
PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.
HAE or ABT: Which Is the Better Value Stock Right Now?
HAE vs. ABT: Which Stock Is the Better Value Option?
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors.
Should Edwards Lifesciences Stock Stay in Your Portfolio Now?
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check.
NEOG Prelim Q2 Earnings Meet, '25 Sales View Down, Stock Falls
NEOG's Food Safety business witnesses a slight year-over-year decrease in revenues for the second quarter of fiscal 2025.
Macroeconomic Woes, Competition Weigh on TMO's Stock Performance
The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.
